Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Colorcon
Cerilliant
Chinese Patent Office
Queensland Health
Baxter
Moodys
Mallinckrodt
Deloitte

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,841,310

« Back to Dashboard

Summary for Patent: 8,841,310
Title:Combinations of a pyrimidine containing NNRTI with RT inhibitors
Abstract: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
Inventor(s): Stoffels; Paul (Hoogstraten, BE)
Assignee: Janssen R & D Ireland (Eastgate Village, Eastgate Little Island, Co. Cork, IE)
Application Number:12/574,881
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,841,310
Patent Claim Types:
see list of patent claims
Compound; Formulation; Composition; Dosage form; Use; Device;

Drugs Protected by US Patent 8,841,310

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc COMPLERA emtricitabine; rilpivirine hydrochloride; tenofovir disoproxil fumarate TABLET;ORAL 202123-001 Aug 10, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF HIV INFECTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,841,310

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03103275Sep 3, 2003
03103319Sep 8, 2003
03103335Sep 10, 2003
03103668Oct 2, 2003

Non-Orange Book US Patents Family Members for Patent 8,841,310

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,080,551 HIV inhibiting pyrimidines derivatives ➤ Sign Up
9,580,392 HIV replication inhibiting pyrimidines ➤ Sign Up
7,125,879 HIV inhibiting pyrimidines derivatives ➤ Sign Up
8,101,629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino]benzonitrile ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,841,310

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1610 ➤ Sign Up
African Regional IP Organization (ARIPO) 2109 ➤ Sign Up
African Regional IP Organization (ARIPO) 2296 ➤ Sign Up
African Regional IP Organization (ARIPO) 2487 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Julphar
Moodys
Citi
McKesson
Colorcon
McKinsey
Merck
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.